BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Goserelin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Goserelin\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06225284-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Goserelin: Phase 2 readout est. (NCT06225284)
DESCRIPTION:Goserelin\, phase 2.\nStudy: Neoadjuvant Chemotherapy With or W
 ithout GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer 
 Patients\nEstimated primary completion: December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/goserelin#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06225284
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02476786-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Goserelin: Phase 2 readout est. (NCT02476786)
DESCRIPTION:Goserelin\, phase 2.\nStudy: Endocrine Treatment Alone for Elde
 rly Patients With Estrogen Receptor Positive Operable Breast Cancer and Lo
 w Recurrence Score\nEstimated primary completion: 31 January 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/goserelin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT02476786
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01786265-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Goserelin: Phase 2 readout est. (NCT01786265)
DESCRIPTION:Goserelin\, phase 2.\nStudy: Finite Androgen Ablation With or W
 ithout Abiraterone Acetate and Prednisone in Treating Patients With Recurr
 ent Prostate Cancer\nEstimated primary completion: 1 February 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/goserelin#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT01786265
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07310420-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Goserelin: Phase 1 readout est. (NCT07310420)
DESCRIPTION:Goserelin\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 
 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Ca
 ncer\nEstimated primary completion: 30 March 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/goserelin#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07310420
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06523530-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Goserelin: Phase 4 readout est. (NCT06523530)
DESCRIPTION:Goserelin\, phase 4.\nStudy: Effect of a GnRH Analog on Hepatic
  Steatosis\nEstimated primary completion: April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/goserelin#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06523530
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07552480-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Goserelin: Phase na readout est. (NCT07552480)
DESCRIPTION:Goserelin\, phase na.\nStudy: Clinical Study on the Preservatio
 n of Ovarian Function Following Hematopoietic Stem Cell Transplantation in
  Patients With Malignant Hematologic Diseases Using Goserelin\nEstimated p
 rimary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/goserelin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07552480
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07552506-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Goserelin: Phase na readout est. (NCT07552506)
DESCRIPTION:Goserelin\, phase na.\nStudy: Clinical Study on the Preservatio
 n of Ovarian Function in Patients With Aplastic Anemia Following Allogenei
 c Hematopoietic Stem Cell Transplantation Using Goserelin\nEstimated prima
 ry completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/goserelin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07552506
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07552493-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Goserelin: Phase na readout est. (NCT07552493)
DESCRIPTION:Goserelin\, phase na.\nStudy: Clinical Study on the Preservatio
 n of Ovarian Function Following Autologous Hematopoietic Stem Cell Transpl
 antation Using Goserelin\nEstimated primary completion: 1 May 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/goserelin#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07552493
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06455969-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Goserelin: Phase 4 readout est. (NCT06455969)
DESCRIPTION:Goserelin\, phase 4.\nStudy: Adaptions and Resiliency to Multi-
 Stressor OpeRations\nEstimated primary completion: August 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/goserelin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06455969
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04734730-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270823
DTEND;VALUE=DATE:20270824
SUMMARY:Goserelin: Phase 2 readout est. (NCT04734730)
DESCRIPTION:Goserelin\, phase 2.\nStudy: Talazoparib With Androgen Deprivat
 ion Therapy and Abiraterone for the Treatment of Castration Sensitive Pros
 tate Cancer\nEstimated primary completion: 23 August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/goserelin#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04734730
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06582446-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Goserelin: Phase 2 readout est. (NCT06582446)
DESCRIPTION:Goserelin\, phase 2.\nStudy: Artificial Intelligence to Persona
 lize Prostate Cancer Treatment (the HypoElect Trial)\nEstimated primary co
 mpletion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/goserelin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06582446
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Goserelin: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Goserelin\, phase 2.\nStudy: Fudan University Shanghai Cancer C
 enter Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/goserelin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158021-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Goserelin: Phase 2 readout est. (NCT07158021)
DESCRIPTION:Goserelin\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Pe
 ri-menopausal Women With Breast Cancer\, OFS Trial\nEstimated primary comp
 letion: 1 January 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/goserelin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07158021
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06145308-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Goserelin: Phase 2 readout est. (NCT06145308)
DESCRIPTION:Goserelin\, phase 2.\nStudy: Precision Treatment of Recurrent/M
 etastatic Salivary Gland Carcinoma Guided by Molecular Typing\nEstimated p
 rimary completion: 10 July 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/goserelin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06145308
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07596212-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Goserelin: Phase 1/2 readout est. (NCT07596212)
DESCRIPTION:Goserelin\, phase 1/2.\nStudy: BRE-06: Study to Increase Tolera
 nce to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor
  Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder\nE
 stimated primary completion: September 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/goserelin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07596212
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07801898-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Goserelin: Phase 2 readout est. (NCT07801898)
DESCRIPTION:Goserelin\, phase 2.\nStudy: Neoadjuvant Endocrine Therapy Comb
 ined With Chemotherapy in ER-positive\, HER2-negative Stage I-III Breast C
 ancer\nEstimated primary completion: 30 September 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/goserelin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07801898
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07460752-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Goserelin: Phase 2 readout est. (NCT07460752)
DESCRIPTION:Goserelin\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian 
 Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hor
 mone Receptor Positive Breast Cancer Patients\nEstimated primary completio
 n: 21 December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 goserelin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07460752
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287098-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Goserelin: Phase 2 readout est. (NCT07287098)
DESCRIPTION:Goserelin\, phase 2.\nStudy: A Study of Imlunestrant (LY3484356
 ) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epide
 rmal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer\nEstima
 ted primary completion: January 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/goserelin#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07287098
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05827081-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20290907
DTEND;VALUE=DATE:20290908
SUMMARY:Goserelin: Phase 3 readout est. (NCT05827081)
DESCRIPTION:Goserelin\, phase 3.\nStudy: Phase IIIb Study of Ribociclib + E
 T in Early Breast Cancer\nEstimated primary completion: 7 September 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/goserelin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05827081
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05161195-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20300628
DTEND;VALUE=DATE:20300629
SUMMARY:Goserelin: Phase 4 readout est. (NCT05161195)
DESCRIPTION:Goserelin\, phase 4\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Roll-over Study to Allow Continued Access to Ribociclib\nEstimated prim
 ary completion: 28 June 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/goserelin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05161195
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06282588-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Goserelin: Phase 2/3 readout est. (NCT06282588)
DESCRIPTION:Goserelin\, phase 2/3.\nStudy: Treatment of High-Risk Prostate 
 Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers\nEstimated 
 primary completion: 31 July 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/goserelin#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06282588
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953882-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Goserelin: Phase 2 readout est. (NCT06953882)
DESCRIPTION:Goserelin\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Impact of Omitting Chemo Based on Patient's Selection for ER-Positive\,
  HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy\nEstima
 ted primary completion: September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/goserelin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06953882
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04423211-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Goserelin: Phase 3 readout est. (NCT04423211)
DESCRIPTION:Goserelin\, phase 3.\nStudy: Treating Prostate Cancer That Has 
 Come Back After Surgery With Apalutamide and Targeted Radiation Based on P
 ET Imaging\nEstimated primary completion: 31 December 2032. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/goserelin#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04423211
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03678025-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20330401
DTEND;VALUE=DATE:20330402
SUMMARY:Goserelin: Phase 3 readout est. (NCT03678025)
DESCRIPTION:Goserelin\, phase 3.\nStudy: Standard Systemic Therapy With or 
 Without Definitive Treatment in Treating Participants With Metastatic Pros
 tate Cancer\nEstimated primary completion: 1 April 2033. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/goserelin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03678025
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04513717-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:Goserelin: Phase 3 readout est. (NCT04513717)
DESCRIPTION:Goserelin\, phase 3.\nStudy: Two Studies for Patients With High
  Risk Prostate Cancer Testing Less Intense Treatment for Patients With a L
 ow Gene Risk Score and Testing a More Intense Treatment for Patients With 
 a High Gene Risk Score\, The PREDICT-RT Trial\nEstimated primary completio
 n: 31 December 2033. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 goserelin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04513717
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06348134-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20340701
DTEND;VALUE=DATE:20340702
SUMMARY:Goserelin: Phase 2 readout est. (NCT06348134)
DESCRIPTION:Goserelin\, phase 2.\nStudy: Assessing the Efficacy and Safety 
 of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and
  After Surgery\nEstimated primary completion: 1 July 2034. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/goserelin#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06348134
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07777263-8458@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Goserelin: Phase 3 readout est. (NCT07777263)
DESCRIPTION:Goserelin\, phase 3.\nStudy: ADT De-escalation in Selected High
 -Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS X
 IV)\nEstimated primary completion: December 2035. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/goserelin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07777263
URL:https://assetmemo.bio/drug/goserelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
